|| Checking for direct PDF access through Ovid
Fistulas are most common symptoms of perianal Crohn's disease. Surgical treatment combined with antiTNF-alfa antibodies such as infliximab (IFX) or adalimumab have become a new mode of therapy in fistulising Crohn's disease, which allows to achieve clinical remission. Present the own reults in cpmbined treatment of Crohn's perianal fistulas.Thirty-four patients with Crohn's perianal fistulas have been hospitalized in the period of 2006-2009. Fistulography, endorectal ultrasound with H2O2 have been done inpreop period. Twenty patients (nine females, 11 males, at the age of 16-47) have been enrolled to IFX trial after surgical treatment. All of the patients underwent surgicalprocedures - non-cuting setons were placed during EUA.Every patient showed clinical response to IFX therapy. More than 50% of fistulas closed spontaneously at week 10. CRP were normalized. CDAI and PDAI significantly reduced. After 30 weeks 82.7% of perianal fistulas have been closed.The efficacy of IFX was confirmed in numerous clinical studies. The use of IFX after surgery is indicated in patients showing no response to standard therapeuticprocedures. It's a good alternative to all remaining methods and allows to close perianal fistulas during short period and increase QoL among Crohn's patients.